Please assess the completion status of the following clinical trial:

Trial Title: Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed adenocarcinoma or carcinoma of the stomach, pancreas and biliary tract with unresectable, recurrence or metastatic disease.~* No prior systemic chemotherapy except adjuvant chemotherapy that has completed 6 months prior enrollment.~* Palliative RT to bone but not the primary, main tumor site is permitted.~* At least one measurable lesion over non-radiated site.~* Aged between 20 to 70 years old.~* ECOG Performance Status \<= 1.~* Life expectancy greater than 12 weeks.~* Adequate bone marrow function : absolutely neutrophil count \>= 1.5 x 109/L or WBC \>= 4 x 109/L, hemoglobin \>= 9 g/dl, platelet count 100 x 109/L~* Adequate liver function : ALT \<= 2.5 x ULN and Bilirubin \< 1.5 x ULN~* Adequate renal function: creatinine \< 1.5 x ULN and calculated eGFR\> 50 mL/min.~Exclusion Criteria:~* Major surgery within four weeks prior to study enrolment.~* Patient with Ampulla vater cancer is excluded.~* Patients with suspicious or history of CNS metastasis.~* Patients who with active or uncontrolled infections.~* Patients who have history of myocardial infarction or unstable angina within 6 months before entry.~* Patients with concomitant illness that might be aggravated by chemotherapy.~* Patients who are pregnant or with breast feeding.~* Other concomitant or previously malignancy within 3 yrs except for in situ cervix cancer or squamous cell carcinoma of the skin, stage 0-I colon or breast treated by surgery only and without evidence of relapsed tumor.~* Mental status is not fit for clinical trial~* Fertile men and women unless using a reliable and appropriate contraceptive method.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOLAR (Type: EXPERIMENTAL): Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60\~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).